ClinicalTrials.gg
RecruitingNCT05126160Updated Nov 18, 2021

Immune Score Based Radiomics in Nasopharyngeal Carcinoma

An observational study in Nasopharyngeal Carcinoma, sponsored by Zhejiang Cancer Hospital. Recruiting at 5 sites in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2021-11-18.

Sponsored by Zhejiang Cancer Hospital · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Oct 2022, 4 years 1 month ago, but the record still lists the study as recruiting.
  • Started Nov 2021; still recruiting 5 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
494
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 23 studies in Nasopharyngeal Carcinoma by Zhejiang Cancer Hospital — 6 open to participants now, 8 under way, none of them phase 3. Nasopharyngeal Carcinoma · Zhejiang Cancer Hospital.

Started
2021
with 1 other
Observational
4 of 23
1 open now
Registered
17th of 23
by date

Among the 23 studies in Nasopharyngeal Carcinoma by Zhejiang Cancer Hospital, this one is one of 2 that started in 2021, is one of 4 observational ones, and was the 17th registered.

Nasopharyngeal Carcinoma

683 studies on the registry are indexed under Nasopharyngeal Carcinoma; 270 are open to participants now.

Browse Nasopharyngeal Carcinoma studies →

Open to participants now

6 of the 23 studies in Nasopharyngeal Carcinoma by Zhejiang Cancer Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 186 Nasopharyngeal Carcinoma studies recruiting now, 42 (23%) set no upper age limit and 135 (73%) stop at 75 or younger; 9 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Nasopharyngeal Carcinoma by Zhejiang Cancer Hospital, or all of them as a file.
02

Study summary

In nasopharyngeal carcinoma (NPC), tumor, node and metastasis (TNM) staging system is the main tool for determining treatment strategy and assessment of prognosis. However, the prognoses of patients with the same TNM stage after similar treatment vary widely. The aim of this study is to establish an immune score based radiomic staging system for NPC.

03

Conditions studied

  • Nasopharyngeal Carcinoma
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Non-metastatic NPC patients receive radical radiotherapy with/without induction or concurrent chemotherapy. De novo metastatic NPC patients would receive at least 4 cycles of platinum-based therapy.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients with newly confirmed non-keratinizing/keratinizing carcinoma.

Performance status: 0-1 With normal liver function test (, AST ≤2.5ULN) Renal: ≥60ml/min Without hematopathy,marrow: WBC >4*109/L, HGB>90G/L, and >100*109/L. Written

Exclusion criteria

Exclusion Criteria:

for MRI scan Prior (except adequately treated carcinoma in-situ of the cervix or · basal/squamous cell carcinoma of the skin) Previous chemotherapy or radiotherapy (except non-melanomatous skin cancers outside the intended RT treatment volume) Patient is pregnant or lactating Any severe intercurrent disease, which may bring unacceptable risk or affect the compliance of the trial, for example, unstable cardiac disease requiring treatment, renal disease, chronic hepatitis, diabetes with poor control (fasting plasma glucose >1.5×), or emotional disturbance.

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
494 participants (estimated)
Patient registry
No

Interventions

  • Diagnostic testImmune Score Based Radiomics

    To establish an immune score based radiomic staging system for nasopharyngeal carcinoma

06

What researchers measure

Primary outcomes

  1. Area Under Curve (AUC)

    The AUC of the immune score based radiomic staging system

    Time frame: Median follow-up time of 5 years for the whole group

07

Study locations

5 of 5 sites recruiting
  • Renmin Hospital of Wuhan University
    Wuhan, Hubei 430060, China
    Recruiting
    • Xiangpan Li · Contactrm001227@whu.edu.cn
    • Xiangpan Li · Principal investigator
    • Qingqing Li · Sub investigator
  • Ningbo First Hospital
    Ningbo, Ningbo 315000, China
    Recruiting
    • Pengrong Lou · Contact
    • Pengrong Lou · Principal investigator
    • Jianliang Zhou · Sub investigator
  • Ningbo Medical Center Lihuili Hospital
    Ningbo, Ningbo 315000, China
    Recruiting
    • Miaozhen Lu · Contactlmz2005@yeah.net
    • Miaozhen Lu · Principal investigator
    • Yanping Bei · Sub investigator
  • The First Affiliated Hospital of Wenzhou Medical University
    Wenzhou, Wenzhou 325000, China
    Recruiting
    • Changlin Zou · Contactzcl19670115@163.com
    • Changlin Zou · Principal investigator
    • Raoying Xie · Sub investigator
  • Zhejiang Cancer Hospital
    Hangzhou, Zhejiang 310022, China
    Recruiting
    • Xiaozhong Chen · Contactcxzfyun@sina.com · 571-88128202
    • Caineng Cao · Sub investigator
    • Lei Wang · Sub investigator
    • Shuang Huang · Sub investigator
    • Mengyun Qiang · Sub investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2021 (actual). Primary completion is estimated for Oct 2022, 11 months after the start.

Of 52 observational studies under Nasopharyngeal Carcinoma, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 155. This study's planned 11 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 7, 2021
First posted
Nov 18, 2021
StartActual
Nov 5, 2021
Primary completionEst.
Oct 2022
CompletionEst.
Dec 2027
Last update
Nov 18, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 18, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05126160
Collaborators
Renmin Hospital of Wuhan University, First Affiliated Hospital of Wenzhou Medical University, Ningbo Medical Center Lihuili Hospital, Ningbo No. 1 Hospital
Responsible party
Sponsor
First posted
Nov 18, 2021
Start date
Nov 5, 2021
Primary completion
Oct 2022 (estimated)
Completion
Dec 2027 (estimated)
Last update
Nov 18, 2021

Study contacts

Xiaozhong Chen
Contact
cxzfyun@sina.com
0571-88128202 ext. +86
Xiaozhong Chen
principal investigator · Department of Radiation Oncology, Zhejiang Cancer Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion